Abstract

Aim: Evaluation of the efficacy of single-dose intravitreal Bevacizumab in the management of macular edema due to retinal vein occlusions.

Objectives:

1. To evaluate the efficacy of single-dose intravitreal bevacizumab in the management of macular edema due to retinal vein occlusions in terms of reduction in central macular thickness.
2. To evaluate the efficacy single dose of intravitreal bevacizumab in the management of macular edema due to retinal vein occlusions in terms of improvement in visual acuity.
3. To evaluate the change in the Intraocular pressure in the eyes receiving intravitreal Bevacizumab.

Methods: This study was an Institutional Review Board approved prospective interventional study done in a Retina clinic at a tertiary eye hospital, where 45 patients were enrolled. All patients clinically diagnosed to have retinal vein occlusions with macular edema with all risk factors were enrolled for the study. After informed consent, all participants were subjected to the following examinations, visual acuity was recorded on Snellen’s vision chart, followed by anterior segment evaluation, intraocular pressure, gonioscopy, slit-lamp biomicroscopy with 90D lens and fundus finding were confirmed by indirect ophthalmoscopy. Optical coherence tomography was done in every patient. The diagnosis of macular edema was established by clinical examination and optical coherence tomography was done to quantify central macular thickness (CMT) at baseline, 4 weeks and 8 weeks after a single injection of 1.25 mg (0.05 ml) intravitreal Bevacizumab.

Results: The mean central macular thickness (CMT) at presentation was 482.88 µm ± 173.6 µm (SD). The mean CMT decreased from baseline to 314.3 µm ± 129.9 µm at one month. The mean CMT decreased to 237.1 µm ± 97.08 µm at the end of 2 months which was statistically significant (p < 0.05). The logarithm of minimal angle of resolution (logMAR) vision at presentation 1.043 ± 0.443 improved to 0.690 ± 0.424 and 0.529 ± 0.440 at 1 month and 2 months respectively (p < 0.05). There was no statistically insignificant change in IOP after a single injection of Bevacizumab.

Conclusion: Intravitreal Bevacizumab even in a single dose is effective in the treatment of all types of retinal vein occlusions. There was a statistically significant improvement in visual acuity, the decrease in the central macular thickness was also statistically significant and effects were maintained throughout the follow-up period without any changes in IOP.

Keywords: Retinal Vein Occlusions; Macular Edema; Intravitreal Bevacizumab; Optical Coherence Tomography; Center Macular Thickness; Visual Acuity; Intraocular Pressure

References

1. Hayreh Sohan Singh. “Prevalent misconceptions about acute retinal vascular occlusive disorders”. Progress in Retinal and Eye Research4 (2005): 493-519.
2. Mitchell P., et al. “Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study”. Archives of Ophthalmology10 (1996): 1243-1247.
3. Klein R., et al. “The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study”. Transactions of the American Ophthalmological Society 98 (2000): 133-141.
4. Rogers Sophie., et al. “The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia”. Ophthalmology2 (2010): 313-319.
5. Cugati Sudha., et al. “Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study”. Archives of Ophthalmology5 (2006): 726-732.
6. McIntosh Rachel L., et al. “Natural history of central retinal vein occlusion: an evidence-based systematic review”. Ophthalmology 6 (2010): 1113-1123.
7. Browning DJ. “Retinal vein occlusions Evidence-Based Management”. New York. Springer-Verlag New York (2012).
8. Finkelstein D. “Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion”. Archives of Ophthalmology10 (1992): 1427-1434.
9. Jonas Jost., et al. “Retinal vein occlusions”. Developments in Ophthalmology 47 (2010): 111-135.
10. Nghiem-Buffet S Cohen SY., et al. “Retinal vein occlusions: anti VEGF treatments”. JFA Ophthalmology9 (2009): 679-686.
11. Cheng Kai-Chun and Wen-Chuan Wu. “Intravitreal triamcinolone acetonide for patients with macular edema due to branch retinal vein occlusion”. The Kaohsiung Journal of Medical Sciences7 (2006): 321-330.
12. Ehlers Justis P., et al. “Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion”. Retina9 (2011): 1856-1862.
13. “Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group”. American Journal of Ophthalmology3 (1984): 271-282.
14. “Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report”. Ophthalmology10 (1995): 1425-1433.
15. Kumagai Kazuyuki., et al. “Three treatments for macular edema because of branch retinal vein occlusion: intravitreous bevacizumab or tissue plasminogen activator, and vitrectomy”. Retina 3 (2012): 520-529.
16. Costa Rogério A., et al. “Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study”. Retina 2 (2007): 141-149.
17. Iturralde Diana., et al. “Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study”. Retina3 (2006): 279-284.
18. Figueroa M S., et al. “Results of bevacizumab as the primary treatment for retinal vein occlusions”. The British Journal of Ophthalmology8 (2010): 1052-1056.
19. Epstein David LJ., et al. “Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study”. Ophthalmology 6 (2012): 1184-1189.
20. Algvere Peep V., et al. “Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial”. European Journal of Ophthalmology6 (2011): 789-795.
21. Ali Rasha I., et al. “Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion”. Indian Journal of Ophthalmology4 (2014): 396-399.
22. Pai Sivakami A., et al. “Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion”. American Journal of Ophthalmology4 (2007): 601-606.
23. Hsu Jason., et al. “Intravitreal bevacizumab (avastin) in central retinal vein occlusion”. Retina 8 (2007): 1013-1019.
24. Rabena Melvin D., et al. “Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion”. Retina 4 (2007): 419-425.

Citation

Citation: Vinit Shah., et al. “Evaluation of the Efficacy of Single Dose of Intravitreal Bevacizumab in the Management of Macular Edema due to Retinal Vein Occlusions". Acta Scientific Paediatrics 3.10 (2020): 12-19.

Copyright

Copyright: © 2020 Vinit Shah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.